# The Overlap of Autoimmune Hepatitis in Children and Adults

## Introduction

**Autoimmune hepatitis (AIH)** is a chronic inflammatory liver disease characterized by interface hepatitis, hypergammaglobulinemia, and circulating autoantibodies. While the fundamental immunopathology is shared, AIH in children often presents more acutely, with higher rates of progression to cirrhosis at diagnosis and different autoantibody profiles compared to adults. Med-peds physicians must recognize the spectrum of presentation, apply appropriate diagnostic criteria, and manage immunosuppressive therapy across the lifespan.

## Classification

### Type 1 AIH

Most common form in both children and adults. Positive **anti-nuclear antibody (ANA)** and/or **anti-smooth muscle antibody (ASMA)**. Bimodal age distribution: peaks in adolescence and ages 40-60. Generally favorable response to immunosuppressive therapy.

### Type 2 AIH

Defined by **anti-liver kidney microsomal antibody type 1 (anti-LKM-1)** or **anti-liver cytosol type 1 (anti-LC-1)** antibodies. Predominantly affects **children and young adults**; rare in adults over 40. More aggressive disease course with higher rates of acute liver failure and cirrhosis at presentation. Often requires more intensive and prolonged immunosuppression.

## Epidemiology

Annual incidence: 1-2 per 100,000 in European populations; likely underdiagnosed globally. Female predominance (~3-4:1) in both pediatric and adult populations. In children, prevalence estimates suggest AIH accounts for ~5-10% of pediatric chronic liver disease. Associated with other autoimmune conditions in ~30-50% of patients: **thyroiditis, celiac disease, type 1 diabetes, inflammatory bowel disease**.

## Clinical Presentation

| Feature | Pediatric AIH | Adult AIH |
|---------|--------------|-----------|
| Presentation | Often acute/fulminant (50% with jaundice) | Usually insidious; incidental LFT elevation |
| Cirrhosis at diagnosis | 30-50% | 25-30% |
| Type 2 AIH prevalence | Common | Rare (mostly type 1) |
| Associated autoimmunity | Celiac, T1DM, thyroiditis | Thyroiditis, RA, SLE |
| Overlap syndromes | AIH-PSC overlap more common | AIH-PBC overlap more common |
| Relapse after withdrawal | 60-80% | 50-70% |
| Acute liver failure | More frequent | Less frequent |

### Pediatric Presentation

Often **acute or fulminant** at diagnosis; up to 50% present with jaundice. Some present as acute liver failure with coagulopathy and encephalopathy. **Cirrhosis at diagnosis** is found in 30-50% of children, reflecting delayed recognition. Non-specific symptoms: fatigue, anorexia, abdominal pain. Physical findings: hepatomegaly, splenomegaly, jaundice, spider angiomata.

### Adult Presentation

More commonly **insidious onset** with fatigue, malaise, and elevated transaminases found incidentally. Can present acutely, mimicking viral or drug-induced hepatitis. Cirrhosis at diagnosis in approximately 25-30% of adults. Extrahepatic autoimmune manifestations may dominate the clinical picture initially.

![Clinical presentation spectrum of autoimmune hepatitis across ages](illustration-aih-presentation-spectrum.jpg)

## Diagnosis

### Revised International Autoimmune Hepatitis Group (IAIHG) Criteria

**Simplified scoring system** includes: autoantibodies, IgG level, liver histology, and exclusion of viral hepatitis. Score >=7: definite AIH; score 6: probable AIH.

### Laboratory Findings

**Transaminases**: Elevated, often markedly (10-50x ULN in acute presentations) **IgG**: Elevated in >80% of patients; degree of elevation may correlate with disease activity. **Autoantibodies**: ANA, ASMA, anti-LKM-1, anti-LC-1, anti-SLA (anti-soluble liver antigen, associated with severe disease and relapse) Up to 10-20% of patients may be **seronegative** at presentation; repeat testing and liver biopsy are essential. Exclude viral hepatitis (A, B, C, E), Wilson disease, drug-induced liver injury, and alpha-1 antitrypsin deficiency.

### Liver Biopsy

**Essential for diagnosis** in most cases; confirms interface hepatitis and excludes other diagnoses. Characteristic findings: **interface hepatitis** (lymphoplasmacytic infiltrate at the portal-parenchymal junction), rosette formation, emperipolesis. Fibrosis staging guides prognosis and treatment urgency. In children, biopsy should be performed before initiating steroids whenever safely possible.

## Treatment

### Induction Therapy

**First-line**: Prednisone (or prednisolone) 1-2 mg/kg/day (max 60 mg) in children; 0.5-1 mg/kg/day in adults. Taper steroids gradually over 6-8 weeks while introducing steroid-sparing agent. **Budesonide**: An alternative in non-cirrhotic adults to reduce systemic steroid side effects; less evidence in children. Response is assessed by normalization of transaminases and IgG levels.

### Maintenance Therapy

**Azathioprine**: First-line steroid-sparing agent; 1-2 mg/kg/day in both children and adults. Check **TPMT (thiopurine methyltransferase)** activity before starting to identify patients at risk for myelotoxicity. **Mycophenolate mofetil (MMF)**: Second-line for azathioprine intolerance or failure; increasingly used in both populations. **6-mercaptopurine**: Alternative when azathioprine is not tolerated.

### Treatment Duration and Withdrawal

Minimum **2-3 years** of therapy with sustained biochemical and histologic remission before considering withdrawal. Relapse rates after treatment withdrawal: **60-80% in children**, 50-70% in adults. Type 2 AIH has particularly high relapse rates; many patients require lifelong therapy. Repeat liver biopsy before withdrawal is recommended to confirm histologic remission. Many experts advocate for indefinite maintenance therapy, particularly in children with type 2 AIH.

### Refractory Disease and Salvage Therapy

Consider **tacrolimus**, **cyclosporine**, or **infliximab** for refractory disease. **Rituximab** has been used in selected cases with promising results. Liver transplantation for acute liver failure unresponsive to therapy or decompensated cirrhosis. AIH recurs post-transplant in 20-40% of cases; maintenance immunosuppression is adjusted accordingly.

![Treatment algorithm for autoimmune hepatitis in pediatric and adult patients](illustration-aih-treatment-algorithm.jpg)

## Overlap Syndromes

**AIH-PSC overlap**: More common in children; features of AIH with cholangiographic changes of primary sclerosing cholangitis. Evaluate with **MRCP** in children and adults with AIH who have cholestatic laboratory features or IBD. **AIH-PBC overlap**: Features of both AIH and primary biliary cholangitis; primarily in adults. Overlap syndromes often require combination therapy (immunosuppression plus ursodeoxycholic acid)

## Monitoring and Long-Term Care

Monitor transaminases, IgG, and autoantibody titers every 1-3 months during active disease, then every 3-6 months in remission. Screen for **osteoporosis** due to chronic corticosteroid use (DXA in adults; growth monitoring in children) **Hepatocellular carcinoma (HCC) screening**: Ultrasound every 6 months for patients with cirrhosis. Vaccination against hepatitis A and B; ensure up-to-date immunizations before immunosuppression.

![Long-term monitoring schedule for autoimmune hepatitis](illustration-aih-monitoring-schedule.jpg)

## Clinical Pearls

AIH in children presents more acutely and aggressively than in adults, with higher rates of cirrhosis and acute liver failure at diagnosis. Anti-LKM-1 positive (type 2) AIH is predominantly a pediatric disease with high relapse rates requiring prolonged or lifelong therapy. Up to 20% of AIH patients may be autoantibody-negative at presentation; liver biopsy is essential for diagnosis. AIH-PSC overlap is an important diagnosis to consider in children with AIH and features of cholestasis or IBD. Relapse is common after treatment withdrawal; shared decision-making about treatment duration is essential.

## References

1. Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis. *Nat Rev Dis Primers*. 2018;4:18017.
2. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. *Hepatology*. 2008;48(1):169-176.
3. Deneau MR, El-Matary W, Engel B, et al. Autoimmune hepatitis-primary sclerosing cholangitis overlap syndrome in children. *Hepatology*. 2017;66(5):1687-1697.
4. Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: AASLD guidelines. *Hepatology*. 2020;72(2):671-722.